Illumina Says 'Significant Growth' in Sequencing Demand Drove 12-Percent Rise in Q4 Revenue
February 09, 2010
Illumina Says 'Significant Growth' in Sequencing Demand Drove 12-Percent Rise in Q4 Revenue
The company said it is in discussions with several large genome centers about replacing their Genome Analyzers with the newly launched HiSeq 2000, but stressed it is premature to forecast how many customers will opt to trade up.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Amid Declining Revenues, Illumina Plans to Restructure, Focus on Clinical Market
October 25, 2011 / In Sequence - Illumina Books Orders for More than 135 MiSeqs, Starts Early-Access Shipments
August 2, 2011 / In Sequence - Defective Sequencing Reagents to Cost Illumina up to $23M in 2009; Company Says Problem is Solved
November 3, 2009 / In Sequence - Illumina Obtains More Than 55 Gb from GA; Expects Large NIH Stimulus Awards for Sequencing
July 28, 2009 / In Sequence - MiSeq, Consumables, Services Drive Illumina's Q4 Revenues as it Begins Work on Nanopore Sequencing
January 29, 2013 / In Sequence